Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

The key role of bisphosphonates in the supportive care of cancer patients.

Tolia M, Zygogianni A, Kouvaris JR, Meristoudis C, Margari N, Karakitsos P, Kokakis I, Kardamakis D, Papadimitriou C, Mystakidou K, Tsoukalas N, Kyrgias G, Armonis B, Filippiadis DK, Kelekis AD, Kelekis N, Kouloulias V.

Anticancer Res. 2014 Jan;34(1):23-37. Review.

PMID:
24403442
2.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
3.

Denosumab and the current status of bone-modifying drugs in breast cancer.

Lee BL, Higgins MJ, Goss PE.

Acta Oncol. 2012 Feb;51(2):157-67. doi: 10.3109/0284186X.2011.633555. Epub 2011 Dec 12. Review.

PMID:
22150116
4.

Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.

Li J, Rugo HS.

Breast Dis. 2011;33(2):83-92. doi: 10.3233/BD-2010-0326. Review.

PMID:
22142661
5.

Combinations of bisphosphonates and classical anticancer drugs: a preclinical perspective.

Michailidou M, Holen I.

Recent Results Cancer Res. 2012;192:145-69. doi: 10.1007/978-3-642-21892-7_7. Review.

PMID:
22307374
6.

Bisphosphonates for advanced prostate cancer.

Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006250. Review.

PMID:
17054286
7.

Pharmacotherapy of bone metastases in breast cancer patients.

Petrut B, Simmons C, Broom R, Trinkaus M, Clemons M.

Expert Opin Pharmacother. 2008 Apr;9(6):937-45. doi: 10.1517/14656566.9.6.937. Review.

PMID:
18377337
8.

[The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].

Tanaka T, Kawashima H, Kuratsukuri K, Sugimura K, Nakatani T.

Hinyokika Kiyo. 2006 Jun;52(6):491-4. Japanese.

9.

The use of bisphosphonates in cancer treatment.

Coleman R.

Ann N Y Acad Sci. 2011 Feb;1218:3-14. doi: 10.1111/j.1749-6632.2010.05766.x. Epub 2010 Sep 28. Review.

PMID:
20946581
10.
11.

Optimal management of metastatic bone disease.

Major P.

Eur J Oncol Nurs. 2007;11 Suppl 2:S32-7. Epub 2007 Sep 4. Review.

PMID:
17804294
12.

[Treatment of bone metastases with bisphosphonates].

Gremaud M, Delouche D, Monnerat C.

Rev Med Suisse. 2006 Aug 9;2(75):1861-6. Review. French.

PMID:
16948423
13.

Bisphosphonates for breast cancer.

Pavlakis N, Stockler M.

Cochrane Database Syst Rev. 2002;(1):CD003474. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003474.

PMID:
11869664
14.

Zoledronic acid use in cancer patients: more than just supportive care?

Coleman R, Cook R, Hirsh V, Major P, Lipton A.

Cancer. 2011 Jan 1;117(1):11-23. Review.

PMID:
21235033
15.

New results from the use of bisphosphonates in cancer patients.

Coleman R, Gnant M.

Curr Opin Support Palliat Care. 2009 Sep;3(3):213-8. doi: 10.1097/SPC.0b013e32832f4149. Review.

PMID:
19561507
16.

Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.

Gnant M, Cl├ęzardin P.

Cancer Treat Rev. 2012 Aug;38(5):407-15. doi: 10.1016/j.ctrv.2011.09.003. Epub 2011 Oct 7. Review.

PMID:
21983264
17.

Risks and benefits of bisphosphonates.

Coleman RE.

Br J Cancer. 2008 Jun 3;98(11):1736-40. doi: 10.1038/sj.bjc.6604382. Epub 2008 May 27. Review.

18.
19.

Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease.

Neville-Webbe HL, Coleman RE.

Eur J Cancer. 2010 May;46(7):1211-22. doi: 10.1016/j.ejca.2010.02.041. Epub 2010 Mar 27. Review.

PMID:
20347292
20.

Bisphosphonates for cancer patients: why, how, and when?

Body JJ, Mancini I.

Support Care Cancer. 2002 Jul;10(5):399-407. Epub 2001 Oct 19. Review.

PMID:
12136223

Supplemental Content

Support Center